Yasir Y. Elamin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yasir Y. Elamin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Shereen Rafee
Department of Medical Oncology, St James's Hospital, Dublin, Ireland
2 shared publicationsBryan T. Hennessy
Department of Medical Oncology, Royal College of Surgeons, Beaumont Hospital
1 shared publication- Kathy Gately
Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity College Dublin, St. James’s Hospital, D08 NHY1 Dublin, Ireland
1 shared publication Kenneth J. O′Byrne
Department of Medical Oncology, St James's Hospital, Dublin, Ireland
1 shared publicationNemer Osman
Department of Medical Oncology, St James's Hospital, Dublin, Ireland
1 shared publicationSinead Toomey
Department of Medical Oncology, Royal College of Surgeons, Beaumont Hospital
1 shared publication
Latest Publications
- 23 August 2015
- Published by Springer Nature in Cancer Microenvironment
- Vol. 9 (1) , 33-43
Thymidine Phosphorylase in Cancer; Enemy or Friend?
Thymidine phosphorylase (TP) is a nucleoside metabolism enzyme that plays an important role in the pyrimidine pathway.TP catalyzes the conversion of thymidine to thymine and 2-deoxy-α-D-ribose-1-phosphate (dRib-1-P). Although this reaction is reversible, the main metabolic function of TP is catabolic. TP is identical to the angiogenic factor platelet-derived endothelial-cell growth factor (PD-ECGF). TP is overexpressed in several human cancers in response to cellular stressful conditions like hypoxia, acidosis, chemotherapy and radiotherapy. TP has been shown to promote tumor angiogenesis, invasion, metastasis, evasion of the immune-response and resistance to apoptosis. Some of the biological effects of TP are dependent on its enzymatic activity, while others are mediated through cytokines like interleukin 10 (IL-10), basic fibroblast growth factor (bFGF) and tumour necrosis factor α (TNFα). Interestingly, TP also plays a role in cancer treatment through its role in the conversion of the oral fluoropyrimidine capecitabine into its active form 5-FU. TP is a predictive marker for fluoropyrimidine response. Given its various biological functions in cancer progression, TP is a promising target in cancer treatment. Further translational research is required in this area.
- 23 August 2015
- Published by Springer Nature in Cancer Microenvironment
- Vol. 9 (1) , 33-43
Thymidine Phosphorylase in Cancer; Enemy or Friend?
Thymidine phosphorylase (TP) is a nucleoside metabolism enzyme that plays an important role in the pyrimidine pathway.TP catalyzes the conversion of thymidine to thymine and 2-deoxy-α-D-ribose-1-phosphate (dRib-1-P). Although this reaction is reversible, the main metabolic function of TP is catabolic. TP is identical to the angiogenic factor platelet-derived endothelial-cell growth factor (PD-ECGF). TP is overexpressed in several human cancers in response to cellular stressful conditions like hypoxia, acidosis, chemotherapy and radiotherapy. TP has been shown to promote tumor angiogenesis, invasion, metastasis, evasion of the immune-response and resistance to apoptosis. Some of the biological effects of TP are dependent on its enzymatic activity, while others are mediated through cytokines like interleukin 10 (IL-10), basic fibroblast growth factor (bFGF) and tumour necrosis factor α (TNFα). Interestingly, TP also plays a role in cancer treatment through its role in the conversion of the oral fluoropyrimidine capecitabine into its active form 5-FU. TP is a predictive marker for fluoropyrimidine response. Given its various biological functions in cancer progression, TP is a promising target in cancer treatment. Further translational research is required in this area.
- Open Access
- 31 December 2014
- Published by ClinMed International Library in International Journal of Cancer and Clinical Research
- Vol. 1 (1)
HER2 Positive Gastric And Gastroesophageal Adenocarcinoma; An Irish Tertiary Center Experience
- 31 December 2014
- Published by ClinMed International Library in International Journal of Cancer and Clinical Research
- Vol. 1 (1)
Open AccessHER2 Positive Gastric And Gastroesophageal Adenocarcinoma; An Irish Tertiary Center Experience
- 18 October 2014
- Published by Springer Nature in Cancer Microenvironment
- Vol. 8 (1) , 15-21
Immune Effects of Bevacizumab: Killing Two Birds with One Stone
Angiogenesis or new vessel formation is essential for tumour growth and progression. Therefore, targeting angiogenesis has been an attractive strategy in the treatment ofcancer. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody thattargets vascular endothelial growth factor-A (VEGF-A) - a key molecular player inangiogenesis. Bevacizumumab has shown clinical efficacy in phase III clinical trials inseveral advanced solid malignancies. The clinical efficacy of bevacizumumab isprimarily due to its antiangiogenic effects; however, there are direct antitumor effectsand immunomodulatory effects. Enhancing the immune system to restore itsantitumour activity has been utilized successfully in clinical setting. In this article we willdiscuss the possible immunomodulatory effects of the most clinically usedantiangiogenic agent; bevacizumumab.
- 18 October 2014
- Published by Springer Nature in Cancer Microenvironment
- Vol. 8 (1) , 15-21
Immune Effects of Bevacizumab: Killing Two Birds with One Stone
Angiogenesis or new vessel formation is essential for tumour growth and progression. Therefore, targeting angiogenesis has been an attractive strategy in the treatment ofcancer. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody thattargets vascular endothelial growth factor-A (VEGF-A) - a key molecular player inangiogenesis. Bevacizumumab has shown clinical efficacy in phase III clinical trials inseveral advanced solid malignancies. The clinical efficacy of bevacizumumab isprimarily due to its antiangiogenic effects; however, there are direct antitumor effectsand immunomodulatory effects. Enhancing the immune system to restore itsantitumour activity has been utilized successfully in clinical setting. In this article we willdiscuss the possible immunomodulatory effects of the most clinically usedantiangiogenic agent; bevacizumumab.